Evidence map›Paper›PMID 35741197›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.

Joel Vargas Ahumada, Sofía D González Rueda, Fabio A Sinisterra Solís, Quetzali Pitalúa Cortés, Liliana P Torres Agredo, Jimenez Ríos Miguel, Anna Scavuzzo, Irma Soldevilla-Gallardo, Miguel A Álvarez Avitia, Nora Sobrevilla and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Advances inPharmaceutics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Joel Vargas AhumadaNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.
Sofía D González RuedaNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.
Fabio A Sinisterra SolísNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.ORCID 0000-0001-7594-4979
Quetzali Pitalúa CortésNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.
Liliana P Torres AgredoNuclear Medicine Department, Universidad Autónoma de Bucaramanga, Bucaramanga 680002, Colombia.
Jimenez Ríos MiguelUrological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.
Anna ScavuzzoUrological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.ORCID 0000-0001-9558-8086
Irma Soldevilla-GallardoNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.
Miguel A Álvarez AvitiaMedical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.
Nora SobrevillaMedical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.
Francisco Osvaldo García PérezNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico.ORCID 0000-0002-1781-0793
Instituto Nacional de Cancerología · MXUniversidad Autónoma de Bucaramanga · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine differentiation of prostate cancer (NEDPC) includes de novo presentation and secondary to epigenetic changes, referred as therapy-induced neuroendocrine prostate cancer (t-NEPC). Molecular imaging with prostate-specific membrane antigen (PSMA) and somatostatin analogues positron emission tomography (PET/CT) in NEDPC have not been validated.

Indexed as

molecular imagingneuroendocrine differentiationPET/CTprostate cancer

Identifiers

PMID35741197
PMCPMC9221809
OpenAlexW4281939406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.